Gilles BESIN,Luis BRITO,Stephen G. HOGE,Edward HENNESSY,Mark CORNEBISE,Kerry BENENATO,Staci SABNIS,Michael W. DANNEMAN
申请号：
US16262758
公开号：
US20190314291A1
申请日:
2019.01.30
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.
